Related Experiment Video

Updated: Sep 6, 2025

In Vivo Imaging of Reactive Oxygen Species in a Murine Wound Model
06:40

In Vivo Imaging of Reactive Oxygen Species in a Murine Wound Model

Published on: November 17, 2018

11.1K

Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress

Shunhao Zhang1, Sining Duan1, Zhuojun Xie1

  • 1State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

Frontiers in Pharmacology
|June 27, 2022
PubMed

Insights

The nuclear factor erythroid 2-related factor 2 (NRF2) and kelch-like ECH-associated protein 1 (KEAP1) pathway impacts cancer. Epigenetic modifications of this pathway offer potential therapeutic targets for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • The nuclear factor erythroid 2-related factor 2 (NRF2) and kelch-like ECH-associated protein 1 (KEAP1) pathway is crucial for cellular redox homeostasis and cancer suppression.
  • Dysregulation of the NRF2/KEAP1 pathway can promote oncogenesis and therapy resistance, influenced by epigenetic mechanisms.

Purpose of the Study:

  • To review the role of NRF2/KEAP1 signaling in cancer-related oxidative stress.
  • To explore how epigenetic modifications influence cancer initiation and progression via the NRF2/KEAP1 pathway.
  • To investigate the therapeutic potential of targeting epigenetic changes in NRF2/KEAP1 signaling for cancer treatment.

Main Methods:

  • Literature review of current research on NRF2/KEAP1 signaling in cancer.
  • Analysis of the interplay between epigenetic modifications and NRF2/KEAP1 pathways.
  • Discussion of therapeutic strategies targeting epigenetic regulation of NRF2/KEAP1.

Main Results:

  • The NRF2/KEAP1 pathway plays a dual role in cancer, with both protective and oncogenic functions.
  • Epigenetic alterations significantly modulate NRF2/KEAP1 activity, impacting cancer development.
  • Targeting epigenetic mechanisms within the NRF2/KEAP1 pathway presents a promising avenue for cancer therapy.

Conclusions:

  • Epigenetic regulation of the NRF2/KEAP1 pathway is a critical factor in cancer initiation, progression, and treatment resistance.
  • Modulating epigenetic changes offers a novel therapeutic strategy for overcoming NRF2/KEAP1-driven oncogenesis and therapy resistance.
Keywords:
DNA methylationKEAP1NRF2SFNhistone acetylationncRNAoxidative stress

More Related Videos

Measurements of Physiological Stress Responses in C. Elegans10:36

Measurements of Physiological Stress Responses in C. Elegans

Published on: May 21, 2020

14.1K
Induction and Analysis of Oxidative Stress in Sleeping Beauty Transposon-Transfected Human Retinal Pigment Epithelial Cells10:00

Induction and Analysis of Oxidative Stress in Sleeping Beauty Transposon-Transfected Human Retinal Pigment Epithelial Cells

Published on: December 11, 2020

2.6K

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K